Project Manager, Global Public Health

At Eisai, satisfying unmet medical needs and increasing the benefits healthcare provides to patients, their families, and caregivers is Eisai’s human health care (hhc) mission. We’re a growing pharmaceutical company that is breaking through in neurology and oncology, with a strong emphasis on research and development. Our history includes the development of many innovative medicines, notably the discovery of the world's most widely-used treatment for Alzheimer’s disease. As we continue to expand, we are seeking highly-motivated individuals who want to work in a fast-paced environment and make a difference.  If this is your profile, we want to hear from you.

Eisai’s global health team seeks a motivated and dynamic project manager for its portfolio of programs developing new medicines for diseases with devastating burdens in the developing world. These efforts are focused on malaria, tuberculosis and the neglected tropical diseases (such as lymphatic filariasis, Chagas disease and leishmaniasis), and are conducted in collaboration with prominent academic and non-profit organizations.
Highlights from the late-stage portfolio include a pivotal clinical trial in Sudan for a new mycetoma therapy, a Phase II clinical trial in the Peruvian Amazon for a new malaria medicine and a Phase I study for another novel antimalarial. Innovative early-stage programs include pioneering advanced therapeutic modalities, and harnessing state-of-the-art data science techniques to accelerate drug discovery. These efforts are complemented by initiatives to build African R&D capabilities and develop innovative finance models in global health.
The Project Manager will be a key member of the global health team, responsible for smooth functioning of multiple drug development projects focused on malaria, tuberculosis and the neglected tropical diseases. This is a varied and dynamic position that spans project operations and planning, budgeting, grant management and contracting. The Project Manager will interface with a range of internal stakeholders, including several scientific groups (chemistry, safety, DMPK, CMC), legal and finance, as well as external collaboration partners and grant agencies in the US and internationally.

Project Manager, Global Public Health
 

Eisai has been dedicated for decades to the pursuit of novel therapeutics to improve the lives of people suffering from dementia and their families.  Recognizing the potential for human genetics, data sciences and precision chemistry to disrupt the drug discovery paradigm, Eisai launched the Eisai Center for Genetics Guided Dementia Discovery (G2D2) in 2019 to accelerate the discovery of innovative therapeutics. G2D2 is a unique drug discovery organization driven by a diverse group of passionate, dedicated and collaborative scientists committed to one goal: delivering breakthroughs for patients and their families. All Eisai employees, as part of the company’s human health care (hhc) mission, spend at least 1% of their working time with patients and families to ensure that the innovation we drive is based on an understanding of their real needs.

A historical strength of G2D2, driven by insights from human genetics, is immunodementia: targeting immune-related targets for dementia.  Expanding from this strength to additional themes in the biology of neurodegenerative disorders, we focus not only on how human genetics and other human biology data may identify and validate therapeutic targets with increased likelihood of success in clinical trials, but also how this data guides selection of the best approaches to design new therapeutics and deliver them to the right patient at the right time. Recognizing the obvious alignment between human genetics and nucleic acid modalities, our precision chemistry strategy is to validate human biology hypotheses by utilizing our unique RNA-targeting therapeutic platform. G2D2’s expertise in harnessing molecular complexity (stereochemistry and topology) to successfully discover and develop natural product based therapeutics has been applied to create an evolving unique nucleic acid therapeutic platform that is being employed globally in multiple clinical and pre-clinical programs at Eisai.

G2D2’s cutting-edge 50,000-square-foot facility is strategically located in Cambridge, MA, to accelerate collaborations with leading research institutes in this world-class biotech hub. Our facility is designed around an open-lab concept, enabling scientists with multi-disciplinary backgrounds to work together in a single integrated lab space. Our labs include state-of-the-art capabilities that support the variety of disciplines located at the site, including medicinal and process chemistry, in-vitro and in-vivo biology, microscopy, DMPK, drug safety, chemical and structural biology, automation and screening, an